Hemodialysis does not affect everolimus pharmacokinetics: two cases of patients with metastatic renal cell cancer.
INSERM, UMR1098, Besançon; UMR1098, SFR IBCT, University of Franche-Comté, Besançon, France; Medical Oncology Unit, CHU Minjoz, Besançon. Electronic address: a.thieryvuillemin@mac.com.
A
A
Thiery-Vuillemin
Medical Oncology Unit, CHU Minjoz, Besançon.
E
E
Curtit
Medical Oncology Unit, CHU Minjoz, Besançon.
T
T
Maurina
Pharmacology Unit, CHU Minjoz, Besançon.
D
D
Montange
Osmose Franche Comté, Besançon, France.
C
C
Succi
Medical Oncology Unit, CHU Minjoz, Besançon.
T
T
NGuyen
Medical Oncology Unit, CHU Minjoz, Besançon.
S
S
Kim
Medical Oncology Unit, CHU Minjoz, Besançon.
P
P
Montcuquet
INSERM, UMR1098, Besançon; UMR1098, SFR IBCT, University of Franche-Comté, Besançon, France; Medical Oncology Unit, CHU Minjoz, Besançon.
X
X
Pivot
INSERM, UMR1098, Besançon; Pharmacology Unit, CHU Minjoz, Besançon.
B
B
Royer
D000368:Aged; D000970:Antineoplastic Agents / Q000097:blood / Q000493:pharmacokinetics*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000378:metabolism / Q000601:surgery; D018572:Disease-Free Survival; D000068338:Everolimus; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000601:surgery; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000097:blood / Q000493:pharmacokinetics
D000970:Antineoplastic Agents; D000068338:Everolimus; D020123:Sirolimus